The Lys103Asn mutation of HIV-1 RT: A novel mechanism of drug resistance

Journal of Molecular Biology

Volumn 309, Issue 2, 2001, Pages 437-445

  Hsiou, Yu ^a   Ding, Jianping ^a,b   Das, Kalyan ^a   Clark Jr , Arthur D ^a   Boyer, Paul L ^c   Lewi, Paul ^d   Janssen, Paul A J ^d   Kleim, Jörg Peter ^e   Rösner, Manfred ^e   Hughes, Stephen H ^c   Arnold, Edward ^a  

^a RUTGERS UNIVERSITY   (United States)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e SANOFI   (France)

Author keywords

AIDS; Drug resistance; HIV 1 reverse transcriptase; Non nucleoside inhibitor; X ray crystallography

Indexed keywords

AMINO ACID; ASPARAGINE; HYDROGEN; LOVIRIDE; LYSINE; PROTEIN SUBUNIT; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE;

AMINO ACID SUBSTITUTION; ARTICLE; CROSS RESISTANCE; DRUG BINDING; DRUG RESISTANCE; ENZYME BINDING; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; VIRUS MUTANT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035368238     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2001.4648     Document Type: Article

References (38)

1. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl) -3,4-dihydroquinoxaline-2-(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytine (lamivudine)
2. Human immunodeficiency virus type 1-specific [2′,5′-bis-O-[tert-butyldimethylsilyl]-β-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole- 2″,2″-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type-1-specific non-nucleoside analogues
3. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
4. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients
5. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents
6. Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro
7. Evaluation of the efficacy and tolence of R018893, R089439 (loviride) and placebo in asymptomatic HIV-1-infected patients
8. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
9. AVANTI: Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients
10. Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase (HBY 097): A pharmacokinetic evaluation in HIV-positive patients
11. Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with Zidovudine in a phase II study
12. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride
13. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance
14. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with double-stranded DNA and an antibody Fab fragment at 2.8 Å resolution
15. Crystal structure of human immunodeficiency virus type I reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA
16. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant
17. Structure of HIV-1 RT/TIBO R 86183 reveals similarity in the binding of diverse nonnucleoside inhibitors
18. Structure of HIV-1 reverse transcriptase in a complex with the nonnucleoside inhibitor α-APA R 95845 at 2.8 Å resolution
19. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor
20. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors
21. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HW mutants
22. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance
23. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
24. Phenyl ethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptase
25. High resolution structures of HIV-1 RT from four RT-inhibitor complexes
26. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design
27. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
28. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: Implications of conformational changes for polymerization and inhibition mechanisms
29. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1
30. 3′-Azido-3′deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range immunodefimational changes
31. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids
32. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase
33. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: Loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions
34. Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors and an antibody Fab fragment
35. Processing of X-ray diffraction data collected in oscillation mode
36. Torsion angle dynamics: Reduced variable conformational sampling enhances crystallographic structure refinement